<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751699</url>
  </required_header>
  <id_info>
    <org_study_id>2007011</org_study_id>
    <nct_id>NCT00751699</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Multiple Dose, Parallel Group Study to Evaluate 5 ASA and N Ac 5 ASA Pharmacokinetics Following Administration of Oral Doses of Asacol 2.4 g/Day and Lialda 2.4 g/Day for 7 Days in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated pharmacokinetics of 5-ASA and N-Ac-5-ASA associated with each of 3&#xD;
      regimens of oral mesalamine 2.4 g/day (Lialda 2.4 g/day 2 x 1.2 g every 24 hours, AsacolÂ® 6 x&#xD;
      400 mg every 24 hours, or Asacol 2 x 400 mg every 8 hours). Primary endpoints were 5-ASA area&#xD;
      under the plasma concentration versus time curve from zero to 24 hours (AUC24) and total&#xD;
      5-ASA percent of dose excreted (A'e [%]) over the 24-hour period on Day 7.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic endpoints of primary interest include AUC24 and the amount of 5-ASA excreted in the urine by subjects dosed with Asacol and Lialda.</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asacol 6x400 mg Q24h at 7 am for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asacol 2x400 mg Q8h at 7 am, 3 pm, and 11 pm for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lialda 2x1.2g Q24h at 7 am for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asacol</intervention_name>
    <description>Asacol tablets, 6 tablets per day at 7 am for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asacol</intervention_name>
    <description>Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lialda</intervention_name>
    <description>Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females between 18 and 45 years of age, inclusive, at screening and in good&#xD;
             general health based on medical history, physical examination, and laboratory&#xD;
             evaluation;&#xD;
&#xD;
          -  If female, must be (as documented by patient reported medical history):&#xD;
&#xD;
          -  postmenopausal (at least 1 year without spontaneous menses), or&#xD;
&#xD;
          -  surgically sterile (tubal ligation or hysterectomy), or&#xD;
&#xD;
          -  using acceptable contraception [e.g., sexual partner with non-reversed vasectomy (with&#xD;
             azoospermia in 2 tests), 2 barrier methods (e.g., condom, diaphragm, or spermicide),&#xD;
             or intra-uterine device];&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kg/m2, inclusive;&#xD;
&#xD;
          -  Able to swallow the assigned study medication tablet whole; and,&#xD;
&#xD;
          -  Able to fulfill the requirements of the protocol and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of any condition or gastrointestinal (GI) surgery causing&#xD;
             malabsorption or an effect on GI motility;&#xD;
&#xD;
          -  Any uncontrolled acute disease or major surgical operation requiring hospitalization&#xD;
             within 1 month of screening;&#xD;
&#xD;
          -  History of diabetes, syncope, cardiovascular, hepatic, or renal disease;&#xD;
&#xD;
          -  Uncontrolled chronic diseases such as hypertension, systemic lupus erythematosus, or&#xD;
             rheumatoid arthritis;&#xD;
&#xD;
          -  History of cancer within the last 5 years (except for basal cell carcinoma with a&#xD;
             documented 6-month remission);&#xD;
&#xD;
          -  Any known enzyme-inducer, enzyme-inhibitor, or reported chronic exposure to&#xD;
             enzyme-inducers such as paint solvents or pesticides within 30 days of treatment;&#xD;
&#xD;
          -  Any prescription drug or herbal remedy within 14 days prior to scheduled dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William S Aronstein, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

